ERBB2 and breast cancer: Having said that, all reported results seem very interesting and promising and a new class of nanoagents able to specifically target HER-2+ BC to deliver cytotoxic or contrast agents would allow us to solve two major unmet clinical needs: (i) the insurgence of resistance mechanisms to available TZ-based targeted therapies and (ii) the difficulties encountered in the process of diagnosis.